Why Don't Patients Take Their Phosphate Binders? Online survey findings showed significant challenges with compliance to ...

Patients on kidney dialysis reported better adherence to an investigational phosphate-binding agent designed to be smaller, ...

When people think of kidney disease, they usually think about problems with how the body removes waste—not about skin issues.

In a survey commissioned by Unicycive that was conducted in 2022, kidney disease specialists said that the greatest unmet need in the treatment of hyperphosphataemia with phosphate binders is a ...

(Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today ...

"[The] vote by the CRDAC is a promising development for the chronic kidney disease community ... which are all limited to the phosphate binder class," said Mike Raab, Ardelyx' president and ...

Unicycive Therapeutics (UNCY) announced new patient-reported outcomes data from its pivotal Phase 2 study of OLC as well as from a new survey ...

on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy. XPHOZAH offers a different mechanism ...